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Original article
Clinical relevance of sensitization to lupine in peanut-sensitized
adults
Lupine (Lupinus albus), a member of the legume family,
has been recognized as a novel food since 1996. The bran
and flour of this legume have been supplied for food
manufacturing, wherein it contributes to the fiber and
protein contents, and also to some textural properties,
particularly in bakery products (1). Lupine can be
cultivated in all climates, making it an attractive crop.
The addition of lupine flour to foods was first
permitted in countries like France and the UK (2). The
inclusion of lupine in foods has increased notably in
many European countries during the last decade. Rea-
sons for this development are the import of bakery
products from France and the use of lupine as replace-
ment for potentially genetically modified soy.
The first published report of an allergic reaction to
lupine appeared in 1994 (1), followed by 12 reports until
2006 based on a Pubmed search. Moreover, thermal
processing appears to have no effect on the allergenicity
of lupine (3–5). Therefore, the presence of lupine in
processed food represents a potential risk for allergic
consumers.
Lupine allergy may arise by cross-reactivity in people
who are already allergic to another member of the
Legume family, in particular peanut (1, 2, 4, 6), or by
primary sensitization (7–9).
Serological cross-reactivity between members of the
legume family occurs frequently, but is not always
reflected by clinically relevant allergies (10–12). In 1994,
Hefle et al. (1) investigated cross-reactivity between
peanut and lupine. They showed that five out of seven
(71%) peanut-allergic patients had a positive skin prick
test (SPT) to lupine. The clinical relevance of this
sensitization was not investigated. Moneret-Vautrin et al.
(6) showed that 44% out of 24 peanut-allergic patients
revealed a positive SPT response to both peanut and
lupine, and five out of six patients tested, reacted to
Background: The use of lupine in food has been increasing during the last decade
and allergic reactions to lupine have been reported, especially in peanut-allergic
patients. The frequency and the degree of cross-reactivity to other legumes are
not known. The aim of the study was to investigate the frequency of sensitization
to lupine, and in addition to pea and soy, and its clinical relevance, in peanut-
sensitized patients. Furthermore, to determine the eliciting dose (ED) for lupine
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lupine as determined by double-blind placebo-controlled
food challenge (DBPCFC). This suggests that the use of
lupine is a risk especially for peanut-allergic patients.
In this study, we investigated the frequency of sensi-
tization to lupine and its clinical relevance, and also to
pea and soy, in peanut-sensitized patients. Furthermore,
we determined the eliciting dose (ED) for lupine by
DBPCFC.
Materials and methods
Patients
Ninety-two adult peanut-sensitized patients with or without symp-
toms to peanut, who visited the outpatient clinic of the Department
of Dermatology/Allergology of the University Medical Center
Utrecht between 2003 and 2006, were approached to participate via
an invitation letter. The selection criteria were a SPT to peanut
extract (ALK-Abello´, Nieuwegein, The Netherlands) with the area
of the peanut wheal at least half of the area of the positive control
[ratio ‡ 0.5, corresponding with SPT ‡ 2+ according to Aas et al.
(13)], and/or specific IgE to peanut ‡ 0.7 kU/l (ImmunoCAP,
Phadia, Uppsala, Sweden). These high cut-off levels were chosen to
obtain a higher likelihood that sensitization would be associated
with clinical allergy.
Pregnancy, significant concurrent disease, unstable asthma and
oral medication with corticosteroids or b-blocking agents were the
exclusion criteria.
Thirty-nine patients (42%) met these criteria, agreed to partici-
pate, and gave written informed consent before enrolment in the
study. Detailed histories of allergies to peanut, green pea and soy,
and atopy were obtained by using a standardized questionnaire.
Sixteen patients were unwilling to participate because of lack of
interest (n = 10) or inability to discontinue antihistamines (n = 6).
Thirty-seven patients (40%) did not respond.
This study was reviewed and approved by the Medical Ethical
Committee of the University Medical Center Utrecht.
Skin prick tests and specific IgE measurements
All 39 patients included in the study were subsequently evaluated by
SPT with commercial extracts of peanut, green pea, soy, grass
pollen and birch pollen (ALK-Abello´, Nieuwegein, the Nether-
lands) and with lupine extract prepared in the following way:
Lupine flour (20 g) was suspended in 200 ml phosphate-buffered
saline (PBS, pH 7.4) containing 0.1% phenol, and was stirred
overnight at 4C. After clarifying the suspension by centrifugation
(1800 g, 30 min) and filtration, the supernatant solution was mixed
with an equal volume of glycerol. The resulting solution in PBS-
glycerol (50% v/v) was subsequently sterilized by filtration (0.22 lm
pore size). The protein content of this extract was determined to be
10.2 mg/ml using the Bradford method (14). Ten healthy subjects
were used as negative controls for SPT with lupine extract. Skin prick
test responses in these control subjects were all negative.
Histamine dihydrochloride (10 mg/ml) and the glycerol diluent of
the SPT extracts served as positive and negative controls, respec-
tively (ALK-Abello´). The SPT were performed and recorded as
described by Dreborg (15). Skin prick test were considered positive
when the wheal reaction was 7 mm2 (diameter 3 mm) and greater
than the negative control. Skin prick test responses were expressed
as the ratio of the wheal reaction in millimetres squared, evaluated
by computer scanning (16) divided by the wheal reaction of the
positive control to correct for the individual variance in reactivity
(17). The use of computerized method is recommended to reduce the
measurement error of traditional methods (18). Skin prick test
ratios were regarded positive when the ratios were ‡0.25, i.e. when
the wheal areas were at least 25% of the wheals induced by the
positive control (corresponding with SPT 1+). As one patient had
dermographism, the SPT results of this patient were not included in
the analysis of SPT data.
Specific IgE levels to peanut, lupine, green pea, soy, grass pollen
and birch pollen, were determined in all patients by the Immuno-
CAP (Phadia). An IgE level of ‡ 0.35 kU/l was taken as a positive
result.
Clinical reactivity
Clinical reactivity to lupine was investigated by DBPCFC in 30 of
the 39 peanut-sensitized patients according to the threshold con-
sensus protocol (19) with some modifications (20). Nine patients
were unwilling to participate in this part of the study because of lack
of time (n = 4), anxiety (n = 2), or lack of interest (n = 3). The
lupine flour used was a commercially available mild white lupine
flour (protein content 36.2% by Leco 2000 method, L. albus),
obtained from Magenta Sales in England produced by CANA
(Martigne-Ferchaud, France). The amounts of lupine flour were
0.01 mg, 0.1 mg, 0.5 mg, 1 mg, 10 mg, 100 mg, 300 mg, 1 g, and
3 g. To mask the lupine doses, 5 g of instant mashed potatoes were
added. The validity of the binding was tested by experienced dieti-
cians and by a team of 10 persons. No differences in flavor, texture,
and smell were observed. The hospital pharmacy prepared the
challenge materials. Four similarly prepared placebo doses of 5 g of
instant mashed potatoes were randomly interspersed between the
increasing lupine doses on the same day. The use of interspersed
placebos was chosen because the procedure could be completed in
1 day. The doses were prepared with 15 ml warm water to a final
dose of 20 g. The challenge was discontinued when objective
symptoms occurred or when subjective symptoms lasted for more
than 45 min. The ED was determined as the lowest dose eliciting a
convincing subjective allergic reaction.
All of the challenges were conducted in a hospital setting, with
careful monitoring of the patients. Full emergency treatment was
readily available.
Statistics
Correlations were analyzed with the nonparametric Spearmans
rank test. Differences in proportions between groups were tested
by two-sided Fishers exact test. Calculations were performed
using spss (version 12, SPSS Inc., 2001, Chicago, IL, USA).
P-values < 0.05 were considered statistically significant.
Results
Patient characteristics
Thirty-nine patients with sensitization to peanut entered
the study. The mean age was 33 years (range, 17–57).
Nineteen patients suffered from atopic eczema (49%), 17
from concomitant asthma (44%), and 36 patients
reported pollinosis symptoms (92%). Sensitization to
grass pollen was present in 79% of the study population
and to birch pollen in 85%.
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Skin prick test responses to peanut were positive in
87% of the patients (n = 33), 92% had a positive CAP
(n = 36), and 79% (n = 30) had both a positive SPT and
CAP. Levels of IgE to peanut ranged from <0.35 to
>100 kU/l (median 2.52 kU/l). Skin prick test responses
to peanut ranged from a ratio of 0 to 18.4 when compared
with the positive control. Twenty-nine of 39 patients
(74%) reported symptoms to peanut by history. Three of
these patients were previously challenged with peanut,
which confirmed the diagnosis of peanut allergy.
Co-sensitization to lupine, pea and soy
To further characterize our study population, the grade
of co-sensitization to different legumes was investigated.
The majority (82%) was also sensitized to lupine as
shown by CAP and/or SPT, whereas 55% was sensitized
to pea, and 87% to soy.
The patients were further divided into two sub-groups,
of patients that do have symptoms to peanut and those
who have not, to determine whether clinically relevant
peanut sensitization had an effect on the grade of
co-sensitization to other legumes. Sensitization to legumes
as measured by CAP and SPT in the whole peanut-
sensitized group and in the two sub-groups is summarized
in Table 1. In general, the sensitization frequency to
lupine, green pea and soy was higher as measured by SPT
than by CAP. The sensitization frequency to lupine, pea
and soy as measured by CAP, and to lupine and pea as
determined by SPT tended to be higher in peanut-allergic
patients when compared with patients that were only sen-
sitized, but this difference was not statistically significant.
The overlap of sensitization to lupine, pea, and soy
with sensitization to peanut is demonstrated in Table 2.
About half of peanut-sensitized patients (53%) were
sensitized to all other three legumes, whereas only two
patients (5%) were mono-sensitized to peanut.
As cross-reactivity is certainly a prominent feature of
the IgE response, we studied whether the level of IgE to
peanut was correlated with the level of IgE to the other
legumes. A significant correlation was observed between
the IgE level to peanut and the IgE level to respectively
lupine [correlation coefficient (r) = 0.6, P < 0.01], pea
(r = 0.42, P < 0.01), and soy (r = 0.69, P < 0.01).
There was also a significant correlation between the SPT
reactivity to peanut and lupine (r = 0.36, P = 0.03),
whereas the correlations between peanut and respectively
pea (r = 0.31, P = 0.05), and soy (r = 0.3, P = 0.06)
were borderline significant.
Clinical reactivity to lupine and eliciting doses determined by
DBPCFC
None of the patients reported symptoms to lupine by
history because they were unaware that lupine was used
as a food ingredient and can cause allergic symptoms. In
30 patients, clinical reactivity to lupine was assessed by
DBPCFC, and nine of them (30%) had a positive
DBPCFC. The first symptom reported during all but
one of the challenges was itching in the oral cavity (oral
symptoms; OS), which recurred after subsequent higher
doses (Table 3). Four patients additionally developed
more serious, but still subjective, gastrointestinal symp-
toms (nausea and abdominal pain). In two patients, this
resulted in discontinuation of the challenge because it
lasted for more than 45 min. Dyspnea without an
objective forced expiratory volume in 1 s decrease was
found in three patients. In one of them, this was the first
symptom reported.
All the patients tolerated a dose of 0.1 mg lupine flour
with neither subjective nor objective symptoms, so the no
observed adverse effect level (NOAEL) for our patient
group in this study was 0.1 mg lupine flour based upon
elicitation of subjective reactions. The minimal ED for
subjective symptoms for the individual patients in this
study varied from 0.5 to 3000 mg (Table 3), inducing
Table 1. Sensitization to legumes in peanut-sensitized patients with and without symptoms to peanut (number of patients, %)
Peanut Lupine Green pea Soy
CAP SPT CAP SPT CAP SPT CAP SPT
Peanut-sensitized patients (n = 39) 36/39 (92) 33/38* (87) 21/39 (54) 26/37* (70) 14/39 (36) 18/38* (47) 18/39 (46) 26/38* (68)
Peanut-allergic patients (n = 29) 27/29 (93) 25/29 (86) 18/29 (62) 21/28 (75) 11/29 (38) 14/29 (48) 15/29 (52) 19/29 (66)
Nonpeanut-allergic patients (n = 10) 9/10 (90) 8/9* (89) 3/10 (30) 5/9* (56) 3/10 (30) 4/9* (44) 3/10 (30) 7/9* (78)
Positive IgE: specific IgE ‡ 0.35 kU/l determined by the ImmunoCAP; positive SPT response: ratio ‡ 0.25.
*The SPT response of one peanut-sensitized patient without symptoms was not included, because of dermographism.
One peanut-sensitized patient with symptoms was not tested by SPT with lupine.
Table 2. Number of peanut-sensitized patients with sensitization to other legumes
Lupine Pea Soy n (%)
) ) ) 2 (5)
+ ) ) 3 (8)
+ + ) 1 (3)
+ ) + 7 (18)
+ + + 20 (53)
) ) + 5 (13)
) + ) 0 (0)
) + + 0 (0)
Sensitization: SPT ratio ‡ 0.25 and/or specific IgE ‡ 0.35 kU/l.
+, sensitization present; ), no sensitization.
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mild-to-moderate symptoms. The minimal ED based on
objective symptoms was 1000 mg and consisted of rhinitis
(Table 3). Three patients failed to develop objective
symptoms or subjective symptoms more serious than
OS even at the highest administered dose of 3000 mg
(Table 3).
Sensitization and allergy to lupine in relation to peanut
characteristics
As sensitization to different legumes in our peanut-
sensitized patients frequently occurred, we evaluated
the clinical relevance of these sensitizations separately
(Table 4A).
Twenty-three of 30 (77%) lupine-challenged patients
had a combined sensitization to peanut and lupine, in line
with the co-sensitization frequency in the whole study
population, demonstrating that lupine sensitization fre-
quently occurs. In eight of these 23 lupine-sensitized
patients (35%), lupine allergy was demonstrated by
positive DBPCFC.
Twenty-one patients did not respond during the
challenge, of which 15 (71%) were sensitized to lupine,
demonstrating a low specificity of CAP and/or SPT.
Eight of nine lupine-allergic patients (89%) were lupine-
sensitized, showing a high sensitivity (Table 4A).
To study whether symptoms to peanut had an effect on
the frequency of symptoms to lupine, peanut-allergic
patients were compared with the patients that were only
sensitized. The frequency of symptoms to lupine tended to
be higher in peanut-allergic patients (8/21) than in patients
without symptoms to peanut (1/9), but this difference was
not statistically significant (P = 0.13) (Table 4B).
Sensitization and allergy to pea and soy in relation to peanut
characteristics
Twenty-one of 38 peanut-sensitized patients (55%) were
also sensitized to pea. Six of them (29%) had a positive
history to pea, demonstrating that about one out of three
patients with sensitization to pea had clinical symptoms
(Table 4A).
Regarding soy, 33 out of 38 peanut-sensitized patients
(87%) were also sensitized to soy. Eleven of these 33
patients (33%) reported symptoms to a wide variety of
soy-containing products, whereas three of five nonsoy-
sensitized patients also had a positive history to soy
(Table 4A). Together, these data demonstrate that sensi-
tization to pea or soy might lead to clinical symptoms in
about 30% of the patients, comparable to lupine. Having
symptoms to peanuts or not had no effect on the
frequency of symptoms to pea and soy (P = 0.35 and
P = 0.21, respectively) (Table 4B).
Predictive factors for lupine-allergy
As an increase in the occurrence of allergic reac-
tions to lupine has been suggested, and because many
Table 3. Clinical reactivity to lupine flour during DBPCFC (n = 9*)
Patient
DBPCFC dose (mg)
ED (mg flour)0.01 0.1 0.5 1 10 100 300 1000 3000
L02KP – – – – OS OS OS OS, rhinitis – 10
L11KP – – – – – – – – OS 3000
L18KP – – – – – – – OS OS, nausea 1000
L19KP – – – – – OS OS OS OS 100
L20KP – – – – – – – OS OS 1000
L34KP – – – – Dyspnea Dyspnea Dyspnea, nausea Dyspnea n.t. 10
L36KP – – OS OS OS OS, dyspnea >1 h n.t. n.t. n.t. 0.5
L37KP – – – OS, abdominal pain OS, abdominal pain >1 h, dyspnea n.t. n.t. n.t. n.t. 1
L39KP – – – OS OS nausea >45 min n.t. n.t. n.t. n.t. 1
ED, eliciting dose; OS, oral symptoms; n.t, not tested; –, no symptoms.
*Nine of 30 patients had a positive DBPCFC with lupine.
Table 4. (A) Sensitization in relation to clinical symptoms to lupine, pea and soy in
peanut-sensitized patients (number of patients). (B) Clinical symptoms to lupine,
pea, and soy in relation to symptoms to peanut (number of patients)
Sensitization
to lupine
Sensitization
to pea
Sensitization
to soy
Yes No Yes No Yes No
(A)
Symptoms 8 1 6 1 11 3
No symptoms 15 6 15 16 22 2
Peanut-allergic Nonpeanut-allergic
(B)
Symptoms to lupine
Yes 8 1
No 13 8
Symptoms to pea
Yes 6 1
No 24 8
Symptoms to soy
Yes 12 2
No 18 7
Symptoms to lupine were determined by DBPCFC, and to pea and soy by history.
Sensitization: SPT ratio ‡ 0.25 and/or specific IgE ‡ 0.35 kU/l.
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food-allergic patients are not aware of the use of lupine
in food, it is relevant to estimate risk factors which are
associated with lupine allergy. Therefore, our lupine-
allergic patients were compared with nonlupine-allergic
patients (Table 5). The distribution of sensitization to
lupine, pea, and soy was similar in both groups. In
addition, there was no significant difference in the
frequency of symptoms to peanut, pea, and soy.
Independent predictive values of the IgE level and SPT
response to lupine for lupine allergy could not be found
by logistic regression analyses (data not shown), demon-
strating that the sensitization level to lupine is not useful
for suspecting an allergy to lupine within a peanut-
sensitized population.
Discussion
Allergy to legumes may be mediated by primary sensiti-
zation via ingestion (7, 8, 21) or inhalation (7, 22, 23) or
may be acquired after primary sensitization to pollen (24–
26) or to another legume (27, 28). Although the route of
sensitization and the frequency of allergic reactions to
lupine are unknown, most reactions have been reported in
peanut-allergic patients (1, 2, 4, 6). Therefore, in this
study, the patterns and frequencies of sensitization to
lupine, pea, and soy were analyzed in an unselected
peanut-sensitized population. In addition, clinical symp-
toms to these legumes were evaluated. We chose to focus
not only on peanut-allergic patients but to include all
peanut-sensitized patients, because peanut-sensitized
patients without symptoms to peanut could have symp-
toms to other legumes as well. This is illustrated by the fact
that one peanut-sensitized patient without symptoms to
peanut did have symptoms to lupine during the DBPCFC.
In our population, co-sensitization to lupine (82%),
pea (55%), and soy (87%) frequently occurred, in line
with previous studies (6, 10, 11). The majority of our
patients (53%) was sensitized to all three legumes tested.
It is not known whether this reflects co-sensitization
towards distinct allergens or cross-reactivity. As the level
of peanut-specific IgE was significantly correlated to the
levels of lupine-, pea- and soy-specific IgE, similar IgE
binding properties of these allergens (cross-reactivity)
could be suggested. However, IgE-inhibition experiments
are needed, to investigate and to identify allergens within
lupine responsible for cross-reactivity. Recently, it was
shown that patients allergic to lupine but not to peanut
displayed IgE binding to other lupine allergens when
compared with the patients with a combined allergy (29),
which indicates that there are remarkable differences in
allergen recognition between these two groups of patients.
IgE binding to lupine allergens could not be inhibited by
pre-incubation of the serum with birch pollen, soy flour,
and green pea flour (29). In a few patients, cross-reactivity
was found between peanut (150 kD allergen) and lupine
(18–22 kD allergen) (29). This illustrates also that unique
allergens might be involved in lupine-allergic patients.
Allergy to either lupine or to pea or soy was present in
one-third of the study population, making it a more
common feature than previously reported (12, 30).
However, those previous studies were performed in
children. It might be that the extents of clinically relevant
cross-reactivity are higher in adults when compared with
children because of dietary habits. The percentages of
reactivity to pea and soy are probably somewhat over-
estimated. Clinical symptoms to lupine were confirmed by
DBPCFC, but for pea and soy the same were only
evaluated by history. As soy is usually consumed as an
ingredient and not as a single food, it is more difficult to
attribute symptoms to this allergen in contrast to pea
which is usually eaten as such. Having symptoms to
peanut or not had no effect on the grade of sensitization
to lupine and on the frequency of symptoms to lupine.
This illustrates that the peanut-sensitized patients without
symptoms to peanut have comparable high risks for being
lupine-allergic as the peanut-allergic patients.
There is little information in the literature on the lowest
dose that causes allergic reactions to lupine (6). Our low-
dose challenge data demonstrated that the no-observed-
adverse effect level for this group of eight lupine-allergic
patients was 0.1 mg lupine flour based on the elicitation
of subjective symptoms. Thus, we can conclude, with
90% certainty that 75% of lupine-allergic individuals will
not react to doses of 0.1 mg lupine flour or less. With
objective symptoms, the no-observed adverse effect level
was 1 mg of lupine flour although three of eight patients
experienced only subjective responses even at the highest
dose of 3000 mg. The lowest (cumulative) ED described
previously was 265 mg of lupine flour, inducing abdom-
inal pain and asthma in peanut-allergic patients (6). For
peanut, we recently established the lowest dose that
induced subjective symptoms using the same challenge
protocol (9). The ED for subjective symptoms started
from 0.1 mg peanut flour, and for objective symptoms
from 10 mg, in line with previous reports (31, 32).
Comparing the results of both studies, it appeared that
the ED for lupine is only fivefold higher than that for
peanut. The symptom progression of peanut and lupine
Table 5. Differences between peanut-sensitized patients with and without lupine
allergy
Lupine-allergic
(n = 9)
Lupine tolerant
(n = 21) P-value*
Lupine sensitization 8/9 (89%) 15/20 (75%) 0.29
Median CAP lupine 0.88 (0.50–2.85) 0 (0–0.76) 0.18
Median SPT lupine 0.58 (0.24–0.67) 0.38 (0.21–0.72) 0.31
Sensitization pea 6/9 (67%) 10/20 (50%) 0.23
Sensitization soy 7/9 (78%) 19/20 (95%) 0.20
Symptoms to peanut 8/9 (89%) 13/21 (62%) 0.13
Symptoms to pea 2/9 (22%) 4/21 (19%) 0.36
Symptoms to soy 4/9 (44%) 5/21 (24%) 0.18
*Fishers exact test.
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during the DBPCFC procedure with higher doses was
similar indicating that the allergenicity of lupine might be
more similar to peanut than, for example, to soy, as in
our population soy usually induces mild symptoms.
However, systemic reactions to soy have been described
(33). Because our study included only 8 patients with
clinical symptoms to lupine, further studies are needed in
a larger group of lupine-allergic patients to confirm the
ED findings in this study to a higher degree of statistical
certainty (34).
Considering the potential severity of lupine allergy and
the likelihood that reactions will occur in unsuspecting
peanut-allergic consumers, factors were investigated to
predict which patients were most likely to have lupine
allergy. In our peanut-sensitized study population, no
predictive factors could be identified by information that
is commonly gathered in routine practice.
Food-allergic individuals are typically advised to
employ specific avoidance diets to prevent reactions
(35). The success of avoidance diets implies that food-
allergic patients would be aware of their allergy and the
use of that ingredient in foods. Currently, the EU requires
the declaration of commonly allergenic foods and ingre-
dients derived from those foods on labels of packaged
foods (5). Peanut is included on the existing list of
commonly allergenic foods in the EU. While the preva-
lence of lupine allergy is unknown, our results suggest
that one-third of peanut-allergic individuals could also be
allergic to lupine. As the prevalence of peanut allergy is
approximately 0.5% of the overall population (36), the
prevalence of lupine allergy could be as high as 0.15%.
Furthermore, lupine-allergic patients reacted at doses as
low as 0.5-mg lupine flour so modest exposures could
provoke reactions. So, it is arguably justified that lupine
is added to the EU list since December 2006 (Annex III
A; 2000/13/EG). However, the declaration of lupine on
food labels will be of limited benefit to individuals who
may be unaware of their lupine allergy. This is shown by
the fact that peanut-sensitized individuals are neither
aware of their potential lupine allergy nor about the use
of lupine in foods while clinically relevant sensitization to
lupine occurs with a reasonably high frequency in the
peanut-sensitized population. Moreover, we were unable
to identify any diagnostic criteria other than use of lupine
challenges to identify the subgroups of patients being
lupine-allergic.
Thus, education is important to build awareness
because labeling strategies alone are unlikely to be
sufficient.
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